The effect of Hericium erinaceum on the prevention of chemically induced experimental colitis in rats.
Colitis
Colon
Fungal proteins
Rats
Journal
The Korean journal of internal medicine
ISSN: 2005-6648
Titre abrégé: Korean J Intern Med
Pays: Korea (South)
ID NLM: 8712418
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
05
02
2019
accepted:
18
12
2019
pubmed:
20
6
2020
medline:
25
6
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
The aim of this study is to investigate the effects of the Hericium erinaceum on an experimental colitis model. Twenty-four Wistar albino were included in this study. Rats were divided into three groups. Group 1 (n = 8) was sham group. Group 2 is the group of chemically induced by intrarectal administration of trinitrobenzene sulfonic acid (TNBS) resulting in colitis. Group 3 (n = 8) is the group that was treated 7 days before and 7 days after with H. erinaceum resulting in colitis. The activity of colitis was evaluated macroscopically and microscopically in rats. In other words, nitric oxide (NO) levels, malondialdehyde (MDA), interleukin 6 (IL-6), nuclear factor-kappa B (NF-κB) and, tumor necrosis factor-α (TNF-α) in addition to the myeloperoxidasem (MPO) activities was determined. The rate of TNBS-induced colitis caused to increase the level of MDA activities meaningfully in the colitis group than the control group. The results indicated that MDA (p = 0.001), NO (p = 0.001), IL-6 (p = 0.001), MPO (p = 0.878), TNF-α (p = 0.001), and NF-κB levels of treatment group decreased in the blood and colon tissues because of the H. erinaceum treatment when compared to the colitis group. H. erinaceum treatment was related to the declining of MDA, NF-κB, NO, IL-6, and TNF-α levels. H. erinaceum had a positive effect on the colitis by reducing oxidative damage in blood and tissue.
Sections du résumé
BACKGROUND/AIMS
The aim of this study is to investigate the effects of the Hericium erinaceum on an experimental colitis model.
METHODS
Twenty-four Wistar albino were included in this study. Rats were divided into three groups. Group 1 (n = 8) was sham group. Group 2 is the group of chemically induced by intrarectal administration of trinitrobenzene sulfonic acid (TNBS) resulting in colitis. Group 3 (n = 8) is the group that was treated 7 days before and 7 days after with H. erinaceum resulting in colitis. The activity of colitis was evaluated macroscopically and microscopically in rats. In other words, nitric oxide (NO) levels, malondialdehyde (MDA), interleukin 6 (IL-6), nuclear factor-kappa B (NF-κB) and, tumor necrosis factor-α (TNF-α) in addition to the myeloperoxidasem (MPO) activities was determined.
RESULTS
The rate of TNBS-induced colitis caused to increase the level of MDA activities meaningfully in the colitis group than the control group. The results indicated that MDA (p = 0.001), NO (p = 0.001), IL-6 (p = 0.001), MPO (p = 0.878), TNF-α (p = 0.001), and NF-κB levels of treatment group decreased in the blood and colon tissues because of the H. erinaceum treatment when compared to the colitis group. H. erinaceum treatment was related to the declining of MDA, NF-κB, NO, IL-6, and TNF-α levels.
CONCLUSION
H. erinaceum had a positive effect on the colitis by reducing oxidative damage in blood and tissue.
Identifiants
pubmed: 32550720
pii: kjim.2019.050
doi: 10.3904/kjim.2019.050
pmc: PMC8009150
doi:
Substances chimiques
NF-kappa B
0
Tumor Necrosis Factor-alpha
0
Trinitrobenzenesulfonic Acid
8T3HQG2ZC4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S44-S52Références
Curr Opin Immunol. 1999 Dec;11(6):648-56
pubmed: 10631550
Immunology. 2002 Feb;105(2):137-43
pubmed: 11872088
Int J Biol Macromol. 2017 Apr;97:228-237
pubmed: 28087447
Mediators Inflamm. 2006;2006(5):92642
pubmed: 17392580
Zhongguo Zhong Yao Za Zhi. 2001 Dec;26(12):831-4
pubmed: 12776329
Chem Pharm Bull (Tokyo). 2005 Sep;53(9):1202-3
pubmed: 16141599
Int J Med Mushrooms. 2016;18(3):227-34
pubmed: 27481156
Acta Cir Bras. 2012 Jan;27(1):23-9
pubmed: 22159435
Korean J Intern Med. 2019 Nov;34(6):1279-1286
pubmed: 31495083
Clin Colon Rectal Surg. 2010 Dec;23(4):227-38
pubmed: 22131893
Cell Mol Life Sci. 2006 Jun;63(12):1331-54
pubmed: 16596337
Oncotarget. 2017 Sep 6;8(49):85838-85857
pubmed: 29156761
Int J Mol Sci. 2018 Jan 24;19(2):
pubmed: 29364170
Int J Biol Macromol. 2018 Feb;107(Pt A):1310-1319
pubmed: 28965966
World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):353-60
pubmed: 27602236
Self Nonself. 2010 Oct;1(4):299-309
pubmed: 21487504
Gastroenterol Clin North Am. 2002 Mar;31(1):63-76
pubmed: 12122744
Cytokine. 2014 Dec;70(2):81-6
pubmed: 25132256
Int J Med Mushrooms. 2018;20(5):485-494
pubmed: 29953363
Transl Gastrointest Cancer. 2013 Jan 1;2(1):21-29
pubmed: 23626930
J Immunol. 2000 May 1;164(9):4878-82
pubmed: 10779797
FEBS Lett. 1994 Feb 28;340(1-2):56-8
pubmed: 8119408
Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):191-2
pubmed: 11475133
J Inflamm Res. 2014 Jun 23;7:113-20
pubmed: 25075198
J Transl Med. 2016 Mar 18;14:78
pubmed: 26988860
Drug Des Devel Ther. 2013 Nov 12;7:1341-57
pubmed: 24250223
Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9
pubmed: 17184768
Biosci Biotechnol Biochem. 1992 Feb;56(2):347-8
pubmed: 1368310
Biol Pharm Bull. 2008 Sep;31(9):1727-32
pubmed: 18758067
Gastroenterology. 2011 May;140(6):1756-1767
pubmed: 21530742
Behav Neurol. 2018 May 21;2018:5802634
pubmed: 29951133
Gastroenterology. 1995 Oct;109(4):1344-67
pubmed: 7557106